Wedbush Lowers Earnings Estimates for Telix Pharmaceuticals

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Equities research analysts at Wedbush decreased their Q4 2025 EPS estimates for Telix Pharmaceuticals in a research note issued on Tuesday, October 14th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $0.03 per share for the quarter, down from their previous forecast of $0.04. Wedbush has a “Outperform” rating and a $22.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals’ Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.22 EPS, Q1 2027 earnings at $0.09 EPS, Q2 2027 earnings at $0.09 EPS and Q3 2027 earnings at $0.10 EPS.

TLX has been the topic of several other research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. HC Wainwright lowered their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Citigroup began coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They set a “buy” rating and a $22.00 price target on the stock. Finally, UBS Group lowered their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Stock Up 9.7%

Shares of NASDAQ:TLX opened at $11.01 on Wednesday. Telix Pharmaceuticals has a 1-year low of $8.93 and a 1-year high of $30.36. The firm’s 50 day simple moving average is $10.33 and its two-hundred day simple moving average is $14.20.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth $213,000. Jane Street Group LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth $564,000. Russell Investments Group Ltd. bought a new stake in Telix Pharmaceuticals in the second quarter worth $975,000. Pier Capital LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth $3,037,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.